The DOI matches its Crossref record.
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Abstract
Brief Communications1 July 1998Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with TroglitazoneNorman Gitlin, MD, Neil L. Julie, MD, Charles L. Spurr, MD, Kie N. Lim, MD, and Herbert M. Juarbe, MDNorman Gitlin, MDFrom Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia., Neil L. Julie, MDFrom Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia., Charles L. Spurr, MDFrom Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia., Kie N. Lim, MDFrom Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia., and Herbert M. Juarbe, MDFrom Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-1-199807010-00008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Several oral antihyperglycemic agents are available for management of type 2 diabetes. These agents generally fall into the chemical or function groups sulfonylureas, biguanides, or α-glucosidase inhibitors. Recently, the U.S. Food and Drug Administration approved troglitazone (Rezulin, Parke-Davis, Morris Plains, New Jersey), a thiazolidinedione agent that is unrelated to the aforementioned categories, as a novel oral antihyperglycemic agent. It decreases hepatic glucose output and increases insulin-dependent glucose metabolism in skeletal muscle [1, 2]. It is not an insulin secretagogue. We report two patients who had severe hepatotoxicity associated with troglitazone administration.Patient 1A 44-year-old woman with a history of ...References1. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994; 331:1188-93. Google Scholar2. Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996; 39:701-9. Google Scholar3. Lee WM. Review article: drug-induced hepatotoxicity. Aliment Pharmacol Ther. 1993; 7:477-85. Google Scholar4. Farrell GC. Drug-induced Liver Disease. London: Churchill Livingstone; 1994:247-300. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Emory University School of Medicine and Shady Grove Adventist Hospital, Atlanta, Georgia.Corresponding Author: Norman Gitlin, MD, Emory University School of Medicine, Division of Digestive Diseases, WMB 2101, Pierce Drive, Atlanta, GA 30322.Current Author Addresses: Drs. Gitlin and Lin: Emory University School of Medicine, Division of Digestive Diseases, WMB 2101, Pierce Drive, Atlanta, GA 30322. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTroglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report Brent A. Neuschwander-Tetri , William L. Isley , Julie C. Oki , Sanjay Ramrakhiani , Stella G. Quiason , Nancy J. Phillips , and Elizabeth M. Brunt Metrics Cited byDrug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced FatalitiesDrug compound screening in single and integrated multi-organoid body-on-a-chip systemsIntegrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment—A case study of troglitazoneWhat Is Pharmacoepidemiology?Can Antidiabetic Drugs Improve Male Reproductive (Dys)Function Associated with Diabetes?Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent MannerThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futureDrugs and ToxinsAntidiabetic therapies and male reproductive function: where do we stand?Nonalcoholic Fatty Liver DiseaseProtein extract from the fruit pulp of Momordica charantia potentiate glucose uptake by up-regulating GLUT4 and AMPKImplications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledgeAssessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting DatabaseAnalysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety ReasonsDrug-Induced Liver DiseasePharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetesCharacterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondriaStratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Vascular Complications of Diabetes MellitusNatural product agonists of peroxisome proli
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“Subsequently, several cases of severe liver toxicity have been reported (142), and there have been at least 43 cases of acute hepatic failure, with 28 reported deaths from liver failure in troglitazonetreated patients.”
BackgroundHewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Metadata
- Authors
- Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1998-07-01
- Volume
- 129
- Issue
- 1
- Pages
- 36-38
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2073903529
- Cited by
- 230
- References
- 0
- FWCI
- 23.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone. https://app.cochat.ai/papers/10.7326/0003-4819-129-1-199807010-00008
- The paper
- Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998). Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-129-1-199807010-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.